momenta pharmaceuticals inc

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) 33.6% LOWER; today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition and intravenous fluid volume in adult subjects with short bowel syndrome.

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) 65.8% HIGHER; announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application (ANDA) for enoxaparin sodium for injection filed by Sandoz.

Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox, which is marketed by Sanofi-Aventis (NYSE: SNY).

H&R Block, Inc. (NYSE: HRB) 4.9% HIGHER; reports FY09 EPS from continuing operations of $1.53. Full year revenues were essentially flat at $4.1 billion.

Tax Services revenues grew 1.5% to $3.0 billion, compared to the prior period. Business Services revenues declined 4.7% to $897.8 million from $941.7 million in the prior period due to decreased performance in the Capital Markets business, and a change in reporting relating to accounting for leased employees.

Core Tax and Consulting revenues grew 4.1% in 2009.